Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16751001 | 0.77 | GRIN1 (0.32) | — | |
| SCHEMBL19852918 | 0.75 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL19852916 | 0.73 | GRIN1 (0.34) | — | |
| SCHEMBL19852849 | 0.71 | HSD11B1 (0.44) | HSD11B1 | |
| SCHEMBL15937192 | 0.70 | BDKRB2 (0.38) | BDKRB2 | |
| SCHEMBL19852817 | 0.69 | TSHR (0.41) | BDKRB2 | |
| SCHEMBL19852917 | 0.69 | JAK3 (0.34) | — | |
| SCHEMBL7924811 | 0.68 | POLB (0.33) | — | |
| SCHEMBL18681238 | 0.68 | SLC6A9 (0.40) | HSD11B1 | |
| SCHEMBL24620446 | 0.67 | GRIN2B (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HSD11B1 2081/4885BDKRB2 453/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HSD11B1 2081/4885BDKRB2 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.